– IBIO-201 demonstrates ability to stimulate anti-SARS-CoV-2 immune response in prophylactic studies –
NEW YORK, 10 August 2020 (GLOBE NEWSWIRE) – iBio, Inc. (NYSE AMERICAN: IBIO) (“iBio” or “Company”), a biotechnology corporation and biology contract manufacturing organization, today offered an update to one of its proprietary vaccine candidates designed to prevent SARS virus infection. -CoV-2. iBio is investigating a group of helpers in connection with the molecule of the owner of the iBio proprietary license (“LicKMTM“) Fused to a coronavirus subunit protein (” IBIO-201 “) with the aim of producing a safe and effective vaccine for COVID-19, and especially one for the most vulnerable populations, including the elderly .
Ten separate preclinical study wings for antigen-IBIO-201 adjuvant combinations have been completed. These include combinations distributed through the intramuscular and intranasal pathways, and the data are under evaluation.
Anti-SARS-CoV-2 drop titers in IBIO-201 were observed 21 days after immunization. Titles continued to rise during the 42-day study. Favorable immune profiles of Th1 and Th2 have been observed.
Early functional testing of mouse antiseptics by immunized IBIO-201 mice indicates the presence of antibodies that interfere with the binding of SARS-CoV-2 spik protein sequences to human ACE2 in ish vivo tests. iBio plans to conduct additional IBIO-201 antiserum testing, including further evaluations of neutralizing securities in multiple rating formats. Furthermore, important studies on immune profiling are ongoing to evaluate the links between safety and immune defense, including antigen-specific T cell responses and memory B cell testing. Additional testing for both the IBIO-201 and IBIO-200 is taking place in collaboration with the laboratories of the University of Texas A&M University (“TAMUS”).
“We are encouraged by this pre-clinical data, which demonstrates the ability of IBIO-201 to generate an immune response to SARS-CoV-2 sequences and to neutralize protein interaction,” said Tom Isett, Chairman and CEO and iBio. “We look forward to gaining more insight as we complete data analysis for both of our candidates for the COVID-19 vaccine.”
About iBio COBID-19 Vaccine Development Programs
On March 11, 2020, the Company filed four interim patent applications with the Defense Factory Patent and Trademark Office in support of its COVID-19 vaccine platform. The virus-like particle program (“VLP”) (“IBIO-200”) was subsequently announced on March 18, 2020. LicKM-The Subunit Program (“IBIO-201”) was announced on June 3, 2020. If the program (s) is transferred to clinical trials, the iBio has the ability to rapidly develop and be produced on a clinical and commercial scale in its 130,000 square foot facility in Bryan, Texas. Originally built in 2010 with funding from the U.S. Defense Advanced Research Projects Agency [DARPA], iBio FastPharming Facility® was part of the “Blue Angel” initiative to create factories capable of rapidly distributing medical contraceptives in response to a disease pandemic.
About iBio, Inc.
iBio is a global leader in the production of plant-based biology. Hers FastPharming system® combines vertical farming, automated hydroponics, and glycine engineering technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, bioinks, and other proteins. The Company ‘s subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Production Services. Ibio of FastGlycaneering Development Service ™ includes a range of new glycosylation technologies for high-performance recombinant protein engineering. Furthermore, iBio is developing proprietary products, which include IBIO-100 for the treatment of fibrotic diseases, and vaccines for COVID-19 disease. For more information, visit www.ibioinc.com.
Certain statements in this press release constitute “future statements” within the meaning of federal securities laws. Words such as “can”, “can”, “will”, “should”, “believe”, “expect”, “predict”, “rating”, “continue”, “predict”, “predict”, ” project “,” “plan”, “purpose” or similar expressions, or statements about purpose, belief, or current expectations, are future statements. These future statements are based on current estimates and assumptions and include statements regarding the production of a safe and effective vaccine for COVID-19 and especially one of our most vulnerable populations, including the elderly, planning to perform additional antiseptic testing. Ibio-201. , including further evaluations of neutralizing titers in multiple evaluation formats, and gain more insights as we complete data analysis for both of our COVID-19 vaccine candidates. While the Company believes that these future statements are reasonable, unnecessary trust should not be placed on any such forward-looking statements, which are based on the information available to us at the date of this release. These future statements are subject to a variety of risks and uncertainties, many of which are difficult to predict which may cause actual results to differ materially from current expectations and assumptions from those set or implied by any future statements. . Important factors that may cause actual results to differ materially from current expectations include, inter alia, the Company’s ability to successfully complete the additional testing planned for both SARS-CoV-2, IBIO-201 vaccine candidates. and IBIO-200, and to produce a safe and effective vaccine for COVID-19 disease, the Company’s ability to obtain regulatory approvals for the commercialization of its product candidates, including its COVID-19 vaccines, or to meet persistent regulatory requirements, regulatory constraints regarding its ability to promote or commercialize its product candidates for specific indications, acceptance of its product candidates in the market and successful development, marketing or sale of products, its ability to maintain his license agreements, maintain and continuously increase his patent assets, his ability to create and maintain collaborations, its ability to obtain or maintain the capital or grants needed to fund its study and development activities, its competition, or its ability to retain its key employees and other factors discussed in the Annual Report of the Company for Form 10-K for the year ended June 30, 2019 and subsequent Company registrations with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. The information in this version is released only from the date of this release, and we assume no obligation to update any future statements contained in this release due to new information, upcoming events, or vice versa, except as required by law.